Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Director Sells 10,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the transaction, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. The trade was a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Trading Up 7.4%

Enliven Therapeutics stock traded up $2.48 during mid-day trading on Tuesday, hitting $36.11. 1,833,071 shares of the company’s stock were exchanged, compared to its average volume of 1,121,074. The stock has a market cap of $2.20 billion, a P/E ratio of -21.62 and a beta of 0.29. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $48.53. The stock has a 50 day moving average of $41.32 and a two-hundred day moving average of $30.28.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. As a group, research analysts predict that Enliven Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently made changes to their positions in ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Enliven Therapeutics by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after buying an additional 1,693 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Enliven Therapeutics by 61.3% in the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after buying an additional 80,506 shares during the period. Jane Street Group LLC bought a new stake in shares of Enliven Therapeutics in the first quarter valued at about $578,000. Legal & General Group Plc lifted its stake in shares of Enliven Therapeutics by 52.2% in the second quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after buying an additional 11,058 shares during the period. Finally, Quantbot Technologies LP lifted its stake in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the period. Institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ELVN shares. Guggenheim started coverage on shares of Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 target price on the stock. The Goldman Sachs Group raised their price target on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Stifel Nicolaus initiated coverage on Enliven Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Finally, Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $61.50.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.